PofoliaShared via Pofolia

Acta Pharmaceutica Sinica B· 2025Q1· Review

Progress in peptide and protein therapeutics: Challenges and strategies

Mengyang Liu, Darren M. Svirskis, Thomas Proft, Jacelyn M. S. Loh et al.

Short summary

This review details strategies to overcome barriers limiting peptide and protein therapeutics, such as enzymatic degradation and poor membrane permeability, to enable non-invasive delivery and improve patient adherence.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Peptide and protein therapeutics face limitations including enzymatic degradation, poor membrane permeability, and parenteral administration requirements.
  • Non-invasive delivery strategies (topical, transdermal, oral) are being explored but still face significant biological and physicochemical barriers.
  • Key challenges involve enzymatic degradation in the GI tract and limited epithelial transport, leading to low systemic bioavailability.
  • Innovative strategies discussed include chemical modifications, enzyme inhibitors, penetration enhancers, physical delivery technologies, and nanoparticulate formulations.

AI-generated from the title and abstract; the full text is not read.

Abstract

Peptide- and protein-based therapeutics offer realized and potential benefits to health, due to their potent bioactivity, high specificity, and favorable safety characteristics. However, their widespread clinical application is constrained by inherent limitations, including rapid enzymatic degradation, poor membrane permeability, and a reliance on parenteral administration, which reduces patient adherence. To overcome these challenges, extensive research has explored non-invasive delivery strategies, including topical, transdermal, and oral formulations. Despite promising advances in these delivery strategies, they are yet to overcome substantial biological and physicochemical barriers in peptide and protein therapeutics, such as enzymatic degradation in the gastrointestinal tract, limited epithelial transport, and inherently low systemic bioavailability. This review provides a comprehensive and up-to-date analysis of the structural and physiological barriers influencing peptide and protein bioavailability and therapeutic efficacy. It critically examines key challenges associated with various administration routes, including topical, transdermal, oral (including delivery targeting the brain), and others. Furthermore, it explores innovative strategies to enhance peptide and protein stability and bioavailability, including chemical modifications, enzyme inhibitors, penetration enhancers, physical delivery technologies, and advanced nanoparticulate formulations. Additionally, emerging trends in formulation optimization, regulatory considerations, and translational pathways for clinical implementation are discussed. By addressing these critical challenges and highlighting recent advances, this review serves as a roadmap for the development of next-generation peptide and protein therapeutics with improved stability and efficacy, and enhanced patient adherence, which is needed to fully realize the true potential of this class of therapeutics.

The authors' abstract, as published at the source. Acta Pharmaceutica Sinica B, 2025 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pharmaceutical Science

Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics